Stats by Source
Total, split by cell line (COSMIC CL / DepMap / PubMed) vs tissue (COSMIC primary tissue)
Total = all mutations for this gene across every source.
Cell line = COSMIC Cell Lines Project + DepMap + PubMed.
Tissue = COSMIC primary-tissue (patient tumour) samples.
Total can exceed cell line + tissue: COSMIC tissue-derived models sit only in global, and a peptide can be shared across both.
| Total | Cell line | Tissue | |
|---|---|---|---|
| Mutations | 445 | 68 | 373 |
| Samples | 416 | 65 | 348 |
| Peptides | 339 | 47 | 298 |
Function
SCUBE3 · Signal peptide, CUB domain and EGF like domain containing 3
This gene encodes a member of the signal peptide, complement subcomponents C1r/C1s, Uegf, bone morphogenetic protein-1 and epidermal growth factor-like domain containing protein family. Overexpression of this gene in human embryonic kidney cells results in secretion of a glycosylated form of the protein that forms oligomers and tethers to the cell surface. This gene is upregulated in lung cancer tumor tissue compared to healthy tissue and is associated with loss of the epithelial marker E-cadherin and with increased expression of vimentin, a mesenchymal marker. In addition, the protein encoded by this gene is a transforming growth factor beta receptor ligand, and when secreted by cancer cells, it can be cleaved in vitro to release the N-terminal epidermal growth factor-like repeat domain and the C-terminal complement subcomponents C1r/C1s domain. Both the full length protein and C-terminal fragment can bind to the transforming growth factor beta type II receptor to promote the epithelial-mesenchymal transition and tumor angiogenesis. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Dec 2014].
Isoforms & Proteins
1 transcript · UniProt mapping is sequence-verified (AA-safe)
Each Ensembl transcript (ENST) this gene is mutated on, with its matched UniProt accession.
The mapping is sequence-verified: the UniProt sequence is identical to the transcript translation, so amino-acid positions line up exactly. A * marks an unreviewed (TrEMBL) entry.
Counts are mutations and unique mutant peptides on each transcript.
| Transcript | UniProt | Mutations | Peptides |
|---|---|---|---|
| ENST00000274938 | Q8IX30 | 445 | 339 |
Gene Properties
Recurrent Mutations
All 338 amino-acid changes on canonical ENST00000274938 · needle height = samples · drag the mini-map to zoom
A lollipop / needle plot – the standard way to show recurrent mutations along a protein (as used by cBioPortal and MutationMapper).
X-axis = amino-acid position in the protein.
Needle height & head size = how often that exact amino-acid change was observed (its recurrence). Tall/large heads are mutational hotspots.
The most recurrent changes are labelled; hover any needle for the change, position and counts.
Mutation frequency across cancer types
% of samples with a missense/complex mutation in SCUBE3 · cell line vs tissue
For each cancer type, the fraction of samples that carry at least one missense/complex mutation anywhere in SCUBE3 – counted as distinct samples (a sample counts once no matter how many mutations it has).
Split into cell line and tissue; each cell shows mutated / total and the percentage. Cohorts with <20 samples are omitted. Ordered by combined frequency.
| Cancer type | Cell lines | Tissue samples |
|---|---|---|
| T-Lymphoblastic Leukemia | 8/40 20% | 0/0 0% |
| T-Cell Non-Hodgkins Lymphoma | 1/26 4% | 0/0 0% |
| Melanoma | 8/210 4% | 68/1899 4% |
| Endometrial Carcinoma | 0/42 0% | 23/612 4% |
| Unknown | 0/10 0% | 1/29 3% |
| Glioblastoma | 2/98 2% | 0/0 0% |
| Colorectal Carcinoma | 12/143 8% | 57/3239 2% |
| Gastric Carcinoma | 1/74 1% | 35/1809 2% |
| Gastrointestinal Stromal Tumour | 0/0 0% | 2/133 2% |
| Neuroendocrine Tumour | 6/154 4% | 4/577 1% |
| Cervical Carcinoma | 0/35 0% | 6/422 1% |
| Other Solid Cancers | 1/94 1% | 18/1515 1% |
| Bladder Carcinoma | 0/58 0% | 12/956 1% |
| Other Sarcomas | 1/69 1% | 7/699 1% |
| Squamous Cell Lung Carcinoma | 1/57 2% | 7/810 1% |
| Burkitts Lymphoma | 2/32 6% | 0/196 0% |
| Hepatocellular Carcinoma | 0/46 0% | 18/2210 1% |
| Hodgkins Lymphoma | 0/16 0% | 1/122 1% |
| Biliary Tract Carcinoma | 0/54 0% | 7/950 1% |
| Small Cell Lung Carcinoma | 2/9 22% | 3/752 0% |
| Non-Small Cell Lung Carcinoma | 3/304 1% | 8/1390 1% |
| Esophageal Carcinoma | 0/23 0% | 5/769 1% |
| Prostate Carcinoma | 5/13 38% | 8/2105 0% |
| Non-Cancerous | 0/104 0% | 5/830 1% |
| Head and Neck Carcinoma | 0/85 0% | 9/1574 1% |
| Germ Cell Tumour | 1/25 4% | 0/169 0% |
| Rhabdomyosarcoma | 1/33 3% | 0/171 0% |
| Ovarian Carcinoma | 3/109 3% | 2/998 0% |
| Meningioma | 1/3 33% | 0/252 0% |
| Esophageal Squamous Cell Carcinoma | 2/51 4% | 8/2550 0% |
Mutation Distribution
Where SCUBE3 is mutated · all tissues, split by cell line vs tissue
How many mutations in SCUBE3 were found in each tissue, across the whole database.
Each bar is a tissue (cell-line and tissue names are merged to the standard tissue), split into cell line and tissue (patient tumour) contributions.
This shows the cancer-context where this gene is recurrently altered.
GTEx Expression
Median TPM across 54 healthy tissues
Median gene expression (TPM) in normal, non-cancer human tissues from the GTEx project.
Useful for judging tumour specificity – a strong neoantigen target ideally comes from a gene with low expression in healthy tissues.
Scroll or drag the mini-axis below the chart to browse all tissues.
Mutations
All 445 mutations in SCUBE3
Every mutation record for this gene, across all samples and sources.
The Sample column links to the cell line (cell-line samples) or the tissue type (tissue samples).
Use the Type / Source filters, the search box, and column sorting to explore; each CAN-IMMUNE ID opens the full mutation & peptide view.
| ID | Sample | Transcript | AA Change | CDS | Type | Source | Mutant Peptide | Wild-type Peptide |
|---|